Johnson & Johnson became the latest COVID-19 vaccine maker to offer an update on booster doses Tuesday, when it said data from a Phase 3 trial and the real world found protection against hospitalization and death is greatly improved by a booster jab of its one-shot vaccine.
The company JNJ said the data showed 94% efficacy against mild to severe COVID-19 in the U.S. after two doses, up from the 74% achieved by the single jab. The company said the data confirmed that even one dose offers strong and long-lasting protection.
…
Comments